The case concerns three Takeda patents for Actos that were set to expire in January 2011, and two follow-up patents that were to expire in June 2016. Read more
We expect to receive EIF payments and final settlement payments for the claims lawyers submitted on behalf of our clients during the first half of 2017. Read more
More than 97 percent of the eligible Actos claimants elected to participate in the Settlement Program. Read more
A former GlaxoSmithKline (GSK) executive, who is now a whistleblower, told a Massachusetts federal court last month that Takeda Pharmaceutical executives admitted to a kickback scheme “for t... Read more
After nearly five months following the announcement of the Actos Resolution Program, it appears that lawyers in our firm have garnered overwhelming support for the Resolution Program from la... Read more
Takeda Pharmaceutical Co. has agreed to pay up to $2.4 billion to resolve bladder cancer claims tied to its Type 2 diabetes drug Actos. The settlement will compensate an estimated 10,000 cla... Read more
A $2.3 million verdict was returned against Takeda Pharmaceuticals Inc. last month in an Actos case. A Philadelphia jury concluded that the diabetes drug had been a significant cause of a re... Read more
Lawyers in our firm are continuously being asked about what all our Mass Torts Section is doing. So we will again give an update on activity in the section. Lawyers in the Section will inves... Read more
As we mentioned above, lawyers in the Mass Torts Section at Beasley Allen continue to evaluate and file claims involving bladder cancer during or following usage of Actos, Actoplus Met, Acto... Read more
In another Actos case, a Philadelphia state court jury, ordered Takeda Pharmaceuticals to pay more than $2 million for failing to warn doctors that its diabetes drug Actos could cause bladde... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.